Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.
Identifieur interne : 000567 ( Main/Corpus ); précédent : 000566; suivant : 000568Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.
Auteurs : Kavita Manchanda ; Jasbir Singh ; Ranjeev Bhagat ; Ilmjot Kaur Tiwana ; Harmanjit SinghSource :
- The International journal of risk & safety in medicine [ 1878-6847 ] ; 2021.
English descriptors
- KwdEn :
- Anti-Infective Agents (adverse effects), Anti-Infective Agents (therapeutic use), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (epidemiology), Drugs, Investigational (MeSH), Female (MeSH), Fetus (drug effects), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), India (epidemiology), Off-Label Use (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (virology), Pregnancy (MeSH), Pregnancy Complications, Infectious (drug therapy), Pregnancy Complications, Infectious (epidemiology), Pregnancy Complications, Infectious (virology), Pregnant Women (MeSH), SARS-CoV-2 (MeSH), Steroids (adverse effects), Steroids (therapeutic use).
- MESH :
- chemical , adverse effects : Anti-Infective Agents, Antiviral Agents, Hydroxychloroquine, Steroids.
- chemical , therapeutic use : Anti-Infective Agents, Antiviral Agents, Hydroxychloroquine, Steroids.
- geographic , epidemiology : India.
- drug effects : Fetus.
- drug therapy : COVID-19, Pneumonia, Viral, Pregnancy Complications, Infectious.
- epidemiology : COVID-19, Pneumonia, Viral, Pregnancy Complications, Infectious.
- virology : Pneumonia, Viral, Pregnancy Complications, Infectious.
- chemical : Drugs, Investigational, Female, Humans, Off-Label Use, Pandemics, Pregnancy, Pregnant Women, SARS-CoV-2.
Abstract
Coronavirus disease 2019 (COVID-19) is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) presenting with pulmonary and extra-pulmonary manifestations. The first case was reported in Wuhan, China in December 2019 and it has rapidly progressed to the form of a pandemic. The presentation is mild in about 80 percent of the cases but the disease can also progress to a severe form of respiratory illness leading to acute respiratory distress syndrome (ARDS) and sometimes multi-organ failure, especially in people with other co-morbidities. Pregnant women also appear to be at a greater risk of acquiring a severe infection due to physiological changes during pregnancy. Many drugs with in vitro activity against the virus or an immunomodulatory effect have been considered for repurposing or have been tried as off-label drugs. The safety data regarding the use of newly approved or off-label or investigational drugs in pregnant women is limited and this poses a great challenge for clinicians. Therefore, it is important to know the utility and safety of the medications to avoid untoward adverse effects on pregnant women and fetuses. In this review, we aim to provide an overview of the approved, off-label, unlicensed, new and some promising pharmacological options for their use in the treatment of COVID-19 and the safety profile in pregnancy in an Indian scenario.
DOI: 10.3233/JRS-200060
PubMed: 33386817
Links to Exploration step
pubmed:33386817Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.</title><author><name sortKey="Manchanda, Kavita" sort="Manchanda, Kavita" uniqKey="Manchanda K" first="Kavita" last="Manchanda">Kavita Manchanda</name><affiliation><nlm:affiliation>Fellow in Reproductive Medicine, Milann Fertility Centre, Bangalore, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Jasbir" sort="Singh, Jasbir" uniqKey="Singh J" first="Jasbir" last="Singh">Jasbir Singh</name><affiliation><nlm:affiliation>Associate Professor, Department of Pharmacology, Government Medical College and Rajindra Hospital, Patiala, India.</nlm:affiliation></affiliation></author><author><name sortKey="Bhagat, Ranjeev" sort="Bhagat, Ranjeev" uniqKey="Bhagat R" first="Ranjeev" last="Bhagat">Ranjeev Bhagat</name><affiliation><nlm:affiliation>Assistant Professor, Department of Pathology, Government Medical College and Hospital, Chandigarh, India.</nlm:affiliation></affiliation></author><author><name sortKey="Tiwana, Ilmjot Kaur" sort="Tiwana, Ilmjot Kaur" uniqKey="Tiwana I" first="Ilmjot Kaur" last="Tiwana">Ilmjot Kaur Tiwana</name><affiliation><nlm:affiliation>MBBS Intern, Government Medical College and Rajindra Hospital, Patiala, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Harmanjit" sort="Singh, Harmanjit" uniqKey="Singh H" first="Harmanjit" last="Singh">Harmanjit Singh</name><affiliation><nlm:affiliation>Assistant Professor, Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33386817</idno><idno type="pmid">33386817</idno><idno type="doi">10.3233/JRS-200060</idno><idno type="wicri:Area/Main/Corpus">000567</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000567</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.</title><author><name sortKey="Manchanda, Kavita" sort="Manchanda, Kavita" uniqKey="Manchanda K" first="Kavita" last="Manchanda">Kavita Manchanda</name><affiliation><nlm:affiliation>Fellow in Reproductive Medicine, Milann Fertility Centre, Bangalore, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Jasbir" sort="Singh, Jasbir" uniqKey="Singh J" first="Jasbir" last="Singh">Jasbir Singh</name><affiliation><nlm:affiliation>Associate Professor, Department of Pharmacology, Government Medical College and Rajindra Hospital, Patiala, India.</nlm:affiliation></affiliation></author><author><name sortKey="Bhagat, Ranjeev" sort="Bhagat, Ranjeev" uniqKey="Bhagat R" first="Ranjeev" last="Bhagat">Ranjeev Bhagat</name><affiliation><nlm:affiliation>Assistant Professor, Department of Pathology, Government Medical College and Hospital, Chandigarh, India.</nlm:affiliation></affiliation></author><author><name sortKey="Tiwana, Ilmjot Kaur" sort="Tiwana, Ilmjot Kaur" uniqKey="Tiwana I" first="Ilmjot Kaur" last="Tiwana">Ilmjot Kaur Tiwana</name><affiliation><nlm:affiliation>MBBS Intern, Government Medical College and Rajindra Hospital, Patiala, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Harmanjit" sort="Singh, Harmanjit" uniqKey="Singh H" first="Harmanjit" last="Singh">Harmanjit Singh</name><affiliation><nlm:affiliation>Assistant Professor, Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The International journal of risk & safety in medicine</title><idno type="eISSN">1878-6847</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Infective Agents (adverse effects)</term><term>Anti-Infective Agents (therapeutic use)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>Drugs, Investigational (MeSH)</term><term>Female (MeSH)</term><term>Fetus (drug effects)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>India (epidemiology)</term><term>Off-Label Use (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (virology)</term><term>Pregnancy (MeSH)</term><term>Pregnancy Complications, Infectious (drug therapy)</term><term>Pregnancy Complications, Infectious (epidemiology)</term><term>Pregnancy Complications, Infectious (virology)</term><term>Pregnant Women (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Steroids (adverse effects)</term><term>Steroids (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Infective Agents</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term><term>Steroids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Infective Agents</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term><term>Steroids</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Fetus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term><term>Pneumonia, Viral</term><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term><term>Pneumonia, Viral</term><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Pneumonia, Viral</term><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drugs, Investigational</term><term>Female</term><term>Humans</term><term>Off-Label Use</term><term>Pandemics</term><term>Pregnancy</term><term>Pregnant Women</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19) is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) presenting with pulmonary and extra-pulmonary manifestations. The first case was reported in Wuhan, China in December 2019 and it has rapidly progressed to the form of a pandemic. The presentation is mild in about 80 percent of the cases but the disease can also progress to a severe form of respiratory illness leading to acute respiratory distress syndrome (ARDS) and sometimes multi-organ failure, especially in people with other co-morbidities. Pregnant women also appear to be at a greater risk of acquiring a severe infection due to physiological changes during pregnancy. Many drugs with in vitro activity against the virus or an immunomodulatory effect have been considered for repurposing or have been tried as off-label drugs. The safety data regarding the use of newly approved or off-label or investigational drugs in pregnant women is limited and this poses a great challenge for clinicians. Therefore, it is important to know the utility and safety of the medications to avoid untoward adverse effects on pregnant women and fetuses. In this review, we aim to provide an overview of the approved, off-label, unlicensed, new and some promising pharmacological options for their use in the treatment of COVID-19 and the safety profile in pregnancy in an Indian scenario.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33386817</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-6847</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>The International journal of risk & safety in medicine</Title><ISOAbbreviation>Int J Risk Saf Med</ISOAbbreviation></Journal><ArticleTitle>Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.</ArticleTitle><Pagination><MedlinePgn>3-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JRS-200060</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) presenting with pulmonary and extra-pulmonary manifestations. The first case was reported in Wuhan, China in December 2019 and it has rapidly progressed to the form of a pandemic. The presentation is mild in about 80 percent of the cases but the disease can also progress to a severe form of respiratory illness leading to acute respiratory distress syndrome (ARDS) and sometimes multi-organ failure, especially in people with other co-morbidities. Pregnant women also appear to be at a greater risk of acquiring a severe infection due to physiological changes during pregnancy. Many drugs with in vitro activity against the virus or an immunomodulatory effect have been considered for repurposing or have been tried as off-label drugs. The safety data regarding the use of newly approved or off-label or investigational drugs in pregnant women is limited and this poses a great challenge for clinicians. Therefore, it is important to know the utility and safety of the medications to avoid untoward adverse effects on pregnant women and fetuses. In this review, we aim to provide an overview of the approved, off-label, unlicensed, new and some promising pharmacological options for their use in the treatment of COVID-19 and the safety profile in pregnancy in an Indian scenario.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manchanda</LastName><ForeName>Kavita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fellow in Reproductive Medicine, Milann Fertility Centre, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Jasbir</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Associate Professor, Department of Pharmacology, Government Medical College and Rajindra Hospital, Patiala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagat</LastName><ForeName>Ranjeev</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Assistant Professor, Department of Pathology, Government Medical College and Hospital, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiwana</LastName><ForeName>Ilmjot Kaur</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>MBBS Intern, Government Medical College and Rajindra Hospital, Patiala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Harmanjit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Assistant Professor, Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Risk Saf Med</MedlineTA><NlmUniqueID>9100907</NlmUniqueID><ISSNLinking>0924-6479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037841" MajorTopicYN="N">Pregnant Women</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Coronavirus</Keyword><Keyword MajorTopicYN="Y">fetus</Keyword><Keyword MajorTopicYN="Y">pregnancy</Keyword><Keyword MajorTopicYN="Y">safety</Keyword><Keyword MajorTopicYN="Y">teratogenic effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>2</Day><Hour>12</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33386817</ArticleId><ArticleId IdType="pii">JRS200060</ArticleId><ArticleId IdType="doi">10.3233/JRS-200060</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000567 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000567 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33386817
|texte= Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33386817" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |